SCHEMBL1696134

SCHEMBL1696134

O=C(O)C1C[C@H](O)CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3262657 1.00 CYP2D6 (0.60)
SCHEMBL19307 1.00
SCHEMBL22792 1.00
SCHEMBL200243 1.00
SCHEMBL85624 1.00
SCHEMBL1995473 1.00
SCHEMBL6858335 1.00 CYP2D6 (0.60)
SCHEMBL21185 1.00
SCHEMBL21184 1.00
SCHEMBL2024894 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155371-A1 MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE BASF SE (DE) 2014-06-05 US claimed
EP-2575852-A1 ANTIMICROBIAL PEPTIDES AND PEPTIDE DERIVATIVES DERIVED FROM ONCOPELTUS FASCIATUS AMP Therapeutics GmbH (DE) 2013-04-10 EP claimed
WO-2013014604-A1 MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE BASF SE (DE) 2013-01-31 WO claimed
WO-2011147960-A1 ANTIMICROBIAL PEPTIDES AND PEPTIDE DERIVATIVES DERIVED FROM ONCOPELTUS FASCIATUS AMP-THERAPEUTICS GMBH & CO. KG (DE) 2011-12-01 WO claimed
EP-4608509-A1 NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Institut National de la Santé et de la Recherche Médicale (FR) 2025-09-03 EP disclosed
WO-2024089272-A1 NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2024-05-02 WO disclosed
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-07-06 US disclosed
EP-3643703-A1 EP300/CREBBP INHIBITOR Daiichi Sankyo Co., Ltd. (JP) 2020-04-29 EP disclosed
US-10328051-B2 Proline or proline derivatives for the treatment of dementia SALAMA ZOSER B (DE) 2019-06-25 US disclosed
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed
EP-3344616-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS S.A. (PL) 2018-07-11 EP disclosed
US-20170239215-A1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA SALAMA ZOSER B (DE) 2017-08-24 US disclosed
WO-2000014201-A1 POLYPEPTIDES CONTAINING MODIFIED, NON-NATURAL AMINO ACIDS AND METHODS OF PRODUCTION UNITED STATES SURGICAL CORPORATION (US) 2000-03-16 WO disclosed
WO-2000009558-A1 HEPATITIS C INHIBITOR PEPTIDES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-02-24 WO disclosed
WO-2000008197-A1 METHOD FOR THE PRODUCTION OF AN ANTIBIOTIC AGENT MERCK & CO., INC. (US) 2000-02-17 WO disclosed
WO-1999050415-A2 PROTEASE-ACTIVATED RECEPTOR PAR4 (ZCHEMR2) ZYMOGENETICS, INC. (US) 1999-10-07 WO disclosed
US-5552405-A TREATMENT OF AIDS, ACTIVITY AGAINST RETROVIRUSES BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1996-09-03 US disclosed
EP-0560269-B1 Substituted pyrrolidine derivatives as HIV protease inhibitors BIO MEGA BOEHRINGER INGELHEIM (CA) 1995-05-31 EP disclosed
EP-0560269-A1 Substituted pyrrolidine derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-15 EP disclosed
EP-0053902-B1 PHOSPHINYLALKANOYL SUBSTITUTED PROLINES E.R. Squibb &amp; Sons, Inc. (US) 1985-04-03 EP disclosed